Ling Zhang1, Hua-Ming Mai2, Jing Zheng3, Jia-Wei Zheng1, Yan-An Wang1, Zhong-Ping Qin4, Ke-Lei Li4. 1. Department of Oral and Maxillofacial Surgery, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology Shanghai 200011, China. 2. Department of Oral and Maxillofacial Surgery, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology Shanghai 200011, China ; Department of Oral and Maxillofacial Surgery, College of Stomatology, Guangxi Medical University Nanning 530021, Guangxi Zhuang Autonomous Region, China. 3. Laboratory of Molecular Neuropharmacology, School of Pharmacy East China, University of Science and Technology 130 Meilong Road, Shanghai 200237, China. 4. Special Department of Vascular Anomalies, Linyi Tumor Hospital Linyi 276000, Shandong Province, China.
Abstract
BACKGROUND: Oral propranolol (PRN) has recently been shown to be highly effective for infantile hemangiomas (IHs), and is currently recommended as the first-line treatment of complicated IHs. However, the therapeutic mechanism(s) still remain unclear. METHODS: In this study, we tested hemangioma-derived stem cells for expression of vascular endothelial growth factor (VEGF) in vitro and studied the inhibition of VEGF expression. We used PCR, Elisa, Western blotting and immunohistochemistry in vivo and in vitro trial. RESULTS: The study demonstrated that application of PRN at a "normal" concentration equivalent to plasma concentration did not inhibit proliferation or promote apoptosis of hemangioma derived stem cells (HemSCs) isolated from IH patients. PRN suppressed expression of vascular endothelial growth factor (VEGF) and basic Fibroblast Growth Factor (bFGF) in HemSCs in vitro. Morphological, histological and immunohistological improvement were observed in vivo using murine IH model in which HemSCs pre-treated with PRN were implanted into BALB/c-nu mice. In the pre-treated HemSC grafts, mean micro-vessel density (MVD) significantly decreased and protein levels of VEGF markedly decreased, while bFGF was still detectable. CONCLUSIONS: The results suggested PRN inhibited angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. These findings provide critical insight into the potential mechanisms of PRN action on IH.
BACKGROUND: Oral propranolol (PRN) has recently been shown to be highly effective for infantile hemangiomas (IHs), and is currently recommended as the first-line treatment of complicated IHs. However, the therapeutic mechanism(s) still remain unclear. METHODS: In this study, we tested hemangioma-derived stem cells for expression of vascular endothelial growth factor (VEGF) in vitro and studied the inhibition of VEGF expression. We used PCR, Elisa, Western blotting and immunohistochemistry in vivo and in vitro trial. RESULTS: The study demonstrated that application of PRN at a "normal" concentration equivalent to plasma concentration did not inhibit proliferation or promote apoptosis of hemangioma derived stem cells (HemSCs) isolated from IH patients. PRN suppressed expression of vascular endothelial growth factor (VEGF) and basic Fibroblast Growth Factor (bFGF) in HemSCs in vitro. Morphological, histological and immunohistological improvement were observed in vivo using murine IH model in which HemSCs pre-treated with PRN were implanted into BALB/c-nu mice. In the pre-treated HemSC grafts, mean micro-vessel density (MVD) significantly decreased and protein levels of VEGF markedly decreased, while bFGF was still detectable. CONCLUSIONS: The results suggested PRN inhibited angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. These findings provide critical insight into the potential mechanisms of PRN action on IH.
Authors: Ilona J Frieden; Anita N Haggstrom; Beth A Drolet; Anthony J Mancini; Sheila Fallon Friedlander; Laurence Boon; Sarah L Chamlin; Eulalia Baselga; Maria C Garzon; Amy J Nopper; Dawn H Siegel; Erin W Mathes; Deborah S Goddard; Joyce Bischoff; Paula E North; Nancy B Esterly Journal: Pediatr Dermatol Date: 2005 Sep-Oct Impact factor: 1.588
Authors: Christine Léauté-Labrèze; Eric Dumas de la Roque; Thomas Hubiche; Franck Boralevi; Jean-Benoît Thambo; Alain Taïeb Journal: N Engl J Med Date: 2008-06-12 Impact factor: 91.245
Authors: Anita N Haggstrom; Beth A Drolet; Eulalia Baselga; Sarah L Chamlin; Maria C Garzon; Kimberly A Horii; Anne W Lucky; Anthony J Mancini; Denise W Metry; Brandon Newell; Amy J Nopper; Ilona J Frieden Journal: Pediatrics Date: 2006-09 Impact factor: 7.124
Authors: Zia A Khan; Elisa Boscolo; Arnaud Picard; Sarah Psutka; Juan M Melero-Martin; Tatianna C Bartch; John B Mulliken; Joyce Bischoff Journal: J Clin Invest Date: 2008-07 Impact factor: 14.808
Authors: J Chang; D Most; S Bresnick; B Mehrara; D S Steinbrech; J Reinisch; M T Longaker; A E Turk Journal: Plast Reconstr Surg Date: 1999-01 Impact factor: 4.730
Authors: Pei Yang; Weiye Deng; Yaqian Han; Yingrui Shi; Ting Xu; Juan Shi; Hesham Elhalawani; Yu Zhao; Xiaoxue Xie; Fan Lou; Rong Zhang; Hekun Jin Journal: Am J Cancer Res Date: 2017-04-01 Impact factor: 6.166
Authors: Hannes Hudalla; Thomas Bruckner; Johannes Pöschl; Thomas Strowitzki; Ruben-J Kuon Journal: Arch Gynecol Obstet Date: 2020-02-28 Impact factor: 2.344
Authors: Meerim Park; Hye Lim Jung; Ye Jee Shim; Heung Sik Kim; Hoi Soo Yoon; Sang Kyu Park; Hee Won Cheuh; Mee Jeong Lee; Jae Min Lee; Eun Sil Park; Jae Hee Lee; Yeon-Jung Lim; Young Bae Choi Journal: Pediatr Res Date: 2020-04-20 Impact factor: 3.756
Authors: David Herndon; Karel D Capek; Evan Ross; Jayson W Jay; Anesh Prasai; Amina El Ayadi; Guillermo Foncerrada-Ortega; Elizabeth Blears; Christian Sommerhalder; Kara McMullen; Dagmar Amtmann; Robert Cox; Gabriel Hundeshagen; Kristofer Jennings; Linda E Sousse; Oscar E Suman; Walter J Meyer; Celeste C Finnerty Journal: Ann Surg Date: 2018-09 Impact factor: 12.969